AU698919B2 - C5a receptor antagonists having substantially no agonist activity - Google Patents

C5a receptor antagonists having substantially no agonist activity

Info

Publication number
AU698919B2
AU698919B2 AU80025/94A AU8002594A AU698919B2 AU 698919 B2 AU698919 B2 AU 698919B2 AU 80025/94 A AU80025/94 A AU 80025/94A AU 8002594 A AU8002594 A AU 8002594A AU 698919 B2 AU698919 B2 AU 698919B2
Authority
AU
Australia
Prior art keywords
analogue
human
antibody
seq
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU80025/94A
Other languages
English (en)
Other versions
AU8002594A (en
Inventor
William C Boyar
Nicholas G Galakatos
Jane V Peppard
Jan Van Oostrum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU8002594A publication Critical patent/AU8002594A/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Amend patent request/document other than specification (104) Assignors: CIBA-GEIGY AG
Application granted granted Critical
Publication of AU698919B2 publication Critical patent/AU698919B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
AU80025/94A 1993-12-06 1994-11-16 C5a receptor antagonists having substantially no agonist activity Ceased AU698919B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16259193A 1993-12-06 1993-12-06
US08/162591 1993-12-06
PCT/IB1994/000359 WO1995016033A1 (en) 1993-12-06 1994-11-16 C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY

Publications (2)

Publication Number Publication Date
AU8002594A AU8002594A (en) 1995-06-27
AU698919B2 true AU698919B2 (en) 1998-11-12

Family

ID=22586301

Family Applications (1)

Application Number Title Priority Date Filing Date
AU80025/94A Ceased AU698919B2 (en) 1993-12-06 1994-11-16 C5a receptor antagonists having substantially no agonist activity

Country Status (15)

Country Link
EP (1) EP0733107A1 (fi)
JP (1) JPH09506258A (fi)
CN (1) CN1142854A (fi)
AU (1) AU698919B2 (fi)
BR (1) BR9408265A (fi)
CA (1) CA2176825A1 (fi)
FI (1) FI962319A0 (fi)
HU (1) HUT75990A (fi)
IL (1) IL111792A0 (fi)
MX (1) MXPA99008669A (fi)
NO (1) NO962348L (fi)
NZ (1) NZ274917A (fi)
TW (1) TW429262B (fi)
WO (1) WO1995016033A1 (fi)
ZA (1) ZA949647B (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
JPH11507215A (ja) * 1995-06-05 1999-06-29 ノバルティス・アクチエンゲゼルシャフト アゴニスト活性を実質的にもたないＣ５ａ受容体アンタゴニストおよび製造方法
WO1997022216A1 (en) * 1995-12-13 1997-06-19 Northern Telecom Limited Integrated cellular voice and digital packet data telecommunications systems and methods for their operation
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
TWI767415B (zh) * 2020-11-18 2022-06-11 中國醫藥大學 自動化血液分析系統及自動化血液分析方法
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305615A1 (en) * 1987-09-03 1989-03-08 Immunetech Pharmaceuticals, Inc. Peptide antagonists for the C5a anaphylatoxin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2703764B2 (ja) * 1986-04-28 1998-01-26 シータス オンコロジー コーポレイション 補体成分Ｃ５ａに対するモノクローナル抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305615A1 (en) * 1987-09-03 1989-03-08 Immunetech Pharmaceuticals, Inc. Peptide antagonists for the C5a anaphylatoxin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMMUNOTECH PHARM. 8.03.89 EMBER ET AL 1992 VOL 198 3165-3173 *
J. RETICULOENDOTHELIAL SOCIETY VOL 26 P 711-718 *

Also Published As

Publication number Publication date
MXPA99008669A (es) 2004-09-01
CA2176825A1 (en) 1995-06-15
FI962319A (fi) 1996-06-03
BR9408265A (pt) 1996-12-10
NO962348D0 (no) 1996-06-05
HU9601538D0 (en) 1996-07-29
JPH09506258A (ja) 1997-06-24
AU8002594A (en) 1995-06-27
NZ274917A (en) 1998-03-25
WO1995016033A1 (en) 1995-06-15
FI962319A0 (fi) 1996-06-03
NO962348L (no) 1996-08-05
ZA949647B (en) 1995-06-06
CN1142854A (zh) 1997-02-12
IL111792A0 (en) 1995-01-24
EP0733107A1 (en) 1996-09-25
HUT75990A (en) 1997-05-28
TW429262B (en) 2001-04-11

Similar Documents

Publication Publication Date Title
CA1339210C (en) Recombinant techniques for production of novel natriuretic and vasodilator peptides
EP0308378B2 (en) Tumor necrosis factor (TNF)inhibitory protein and its purification
US5114923A (en) Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5807824A (en) C5A receptor antagonists having substantially no agonist activity
EP0579739A1 (en) Interleukin-8 receptors and related molecules and methods
US5783421A (en) DNA encoding novel polypeptide having Factor Xa inhibitory activity
AU698919B2 (en) C5a receptor antagonists having substantially no agonist activity
WO1996039503A1 (en) C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY AND METHODS FOR PREPARATION
US5837499A (en) DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
EP0210233A1 (en) Brain derivable polypeptide factors and antibodies
US5476839A (en) Basophil granule proteins
CA2046925A1 (en) Pregnancy specific proteins applications
JP3509860B2 (ja) 新規好中球インヒビター
AU741330B2 (en) Rat ST38.2 chemokine
JP4290564B2 (ja) Ｃ５ａアナフィラトキシンの突然変異タンパク質、このような突然変異タンパク質をコードする核酸分子ならびにＣ５ａアナフィラトキシンの突然変異タンパク質の医薬的使用
EP0696198B1 (en) Novel polypeptide having factor xa inhibitory activity
WO1996021006A1 (en) Novel phosphoprotein secreted in the extracellular matrices of mammalian organs and methods for use thereof
EP0693925B1 (en) Production of a recombinant factor xa inhibitor of leech hirudo medicinalis
US20020165354A1 (en) Tumor necrosis factor inhibitory protein and its purification
NZ516533A (en) Use of neutrophil inhibitors in the manufacture of medicaments to inhibit inflammatory responses and neutrophil activity

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired